{"entity":{"id":"nct06344052","kind":"trial","name":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma","aka":[],"tldr":"A phase 2 trial of Vismodegib in basal cell carcinoma, run by Stamford Pharmaceuticals, Inc., now recruiting.","summary":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma is a phase 2 interventional study registered as NCT06344052 by Stamford Pharmaceuticals, Inc., with 80 participants planned, started 2024-04-09 and due to reach its primary completion in 2026-09-30. Interventions recorded: SP-002, Vismodegib. Conditions listed: Basal Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06344052","url":"https://clinicaltrials.gov/study/NCT06344052"}],"tags":["ctgov-ingest"],"related":[],"cancers":["basal-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["vismodegib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06344052","phase":"2","setting":"A Phase 2 Study to Assess the Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma","sponsor":"Stamford Pharmaceuticals, Inc.","enrolled":80,"outcomes":[]},"route":"/trials/nct06344052/","neighbours":{"cancer":[{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/"}],"drug":[{"id":"vismodegib","kind":"drug","name":"Vismodegib","route":"/drugs/vismodegib/"}]}}